File:Proposed positioning of the Liver-Chip within a typical pharma preclinical workflow.webp
Size of this PNG preview of this WEBP file: 800 × 320 pixels. Other resolutions: 320 × 128 pixels | 640 × 256 pixels | 1,024 × 410 pixels | 2,048 × 820 pixels.
Original file (2,048 × 820 pixels, file size: 78 KB, MIME type: image/webp)
File information
Structured data
Captions
Summary
editDescriptionProposed positioning of the Liver-Chip within a typical pharma preclinical workflow.webp |
English: "Typically, pharma utilizes a series of in vitro tests to guide chemical optimization ahead of animal testing. Promising drug candidates then progress to dose-range finding studies ahead of the required studies to enable regulatory approval to enter clinical trial. With the data presented in this investigation, Liver-Chip would be best placed in between the in vitro tests and dose-range finding animal studies. A drug candidate that did not show toxicity in the Liver-Chip, would increase confidence of the scientist that it can pass through animal testing without a liver toxicity flag and proceed into the clinic with a lower likelihood of clinical hepatic signals. A drug candidate that did show toxicity in the Liver-Chip would encourage scientists to stop and think about the relevance of the toxicity to the therapeutic indication and whether there was a potential margin between this finding and the exposure required for clinical efficacy. This would continue to increase the confidence that candidate drugs are entering the phase I clinical trial process with a greater likelihood of approval and may also reduce animal usage by not conducting dose-range finding or regulatory studies." |
Date | |
Source | https://www.nature.com/articles/s43856-022-00209-1 |
Author | Authors of the study: Lorna Ewart, Athanasia Apostolou, Skyler A. Briggs, Christopher V. Carman, Jake T. Chaff, Anthony R. Heng, Sushma Jadalannagari, Jeshina Janardhanan, Kyung-Jin Jang, Sannidhi R. Joshipura, Mahika M. Kadam, Marianne Kanellias, Ville J. Kujala, Gauri Kulkarni, Christopher Y. Le, Carolina Lucchesi, Dimitris V. Manatakis, Kairav K. Maniar, Meaghan E. Quinn, Joseph S. Ravan, Ann Catherine Rizos, John F. K. Sauld, Josiah D. Sliz, William Tien-Street, Dennis Ramos Trinidad, James Velez, Max Wendell, Onyi Irrechukwu, Prathap Kumar Mahalingaiah, Donald E. Ingber, Jack W. Scannell & Daniel Levner |
Licensing
editThis file is licensed under the Creative Commons Attribution 4.0 International license.
- You are free:
- to share – to copy, distribute and transmit the work
- to remix – to adapt the work
- Under the following conditions:
- attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
File history
Click on a date/time to view the file as it appeared at that time.
Date/Time | Thumbnail | Dimensions | User | Comment | |
---|---|---|---|---|---|
current | 15:13, 2 February 2023 | 2,048 × 820 (78 KB) | Prototyperspective (talk | contribs) | Uploaded a work by Authors of the study: Lorna Ewart, Athanasia Apostolou, Skyler A. Briggs, Christopher V. Carman, Jake T. Chaff, Anthony R. Heng, Sushma Jadalannagari, Jeshina Janardhanan, Kyung-Jin Jang, Sannidhi R. Joshipura, Mahika M. Kadam, Marianne Kanellias, Ville J. Kujala, Gauri Kulkarni, Christopher Y. Le, Carolina Lucchesi, Dimitris V. Manatakis, Kairav K. Maniar, Meaghan E. Quinn, Joseph S. Ravan, Ann Catherine Rizos, John F. K. Sauld, Josiah D. Sliz, William Tien-Street, Dennis... |
You cannot overwrite this file.
File usage on Commons
There are no pages that use this file.
File usage on other wikis
The following other wikis use this file:
- Usage on en.wikipedia.org